ArticleStem cell research & therapy2025
FKBP prolyl isomerase 4: a potential target for heart failure and cardioprotective effects via leonurine-pretreated mesenchymal stem cell-derived exosomes.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Empagliflozin-pretreated mesenchymal stem cell-derived extracellular vesicles facilitate cardiac repair via AGGF1.Journal of nanobiotechnology · 2026Article
- Mesenchymal Stem Cell-Derived Exosomes: A Tool for Heart Failure Repair - From Molecular Mechanisms to Clinical Potential.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe use of mesenchymal stem cell-derived exosomes (MSC-EXOs) is a promising strategy for treating heart failure. Pretreatment of MSCs with cardioprotective agents, such as leonurine, has the potential to augment the therapeutic efficacy of their EXO activities. However, the cardioprotective potential of EXOs derived from MSCs pretreated with leonurine (MSCLeo-EXO) remains unexplored.
methodsMSCLeo-EXO were isolated following a 48-hour culture period of the MSCs in a leonurine-supplemented medium. The cardioprotective effects of MSCLeo-EXOs were investigated both in vitro and in vivo via a hypoxia-induced cardiomyocyte injury model, a TGF-β-induced cardiomyocyte fibrosis model, and a mouse model of heart failure. Additionally, the compositions of the MSCLeo-EXOs and control EXOs were compared via miRNA sequencing. Experiments using loss-of-function and overexpression methods were carried out to learn more about the precise processes that underlie the action of MSCLeo-EXOs.
resultsMSCLeo-EXO were successfully isolated and possessed the characteristics of EXOs. Compared with EXOs from untreated MSCs, those from MSCLeo-EXOs inhibited pyroptosis, protected cardiomyocytes from hypoxia-induced apoptosis damage, enhanced cardiac function, and reduced fibrosis and collagen deposition in heart failure model mice. Furthermore, miRNA sequencing revealed that MSCLeo-EXOs contained a greater level of miR-3152-5p. Both in vivo and in vitro, the cardioprotective effects mediated by MSCLeo-EXOs were diminished by miR-3152-5p knockdown. Increased miR-3152-5p mechanistically enhanced the cardioprotective effect of MSCLeo-EXOs by targeting and inhibiting the expression of FKBP prolyl isomerase 4 (FKBP4), reducing fibrosis and inflammatory responses, and mitigating hypoxia-induced cell damage.
conclusionOur findings revealed that pretreatment of MSCs with leonurine increased miR-3152-5p expression in EXOs, which enhanced the cardioprotective effect of MSCLeo-EXOs. In addition, our study is the first to reveal the pivotal role of FKBP4 in heart failure, providing novel insights into the therapeutic potential of exosome-based interventions for this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.